Key player · Company profile
Pfizer Inc.
Named as a key player in 792 of our reports, across 33 regions and countries.
Named as a key player in 792 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
Australia 24
Brazil 24
Canada 24
China 24
Ecuador 24
Egypt 24
France 24
Germany 24
Hong Kong 24
India 24
Italy 24
Japan 24
Kenya 24
Malaysia 24
Mexico 24
New Zealand 24
Philippines 24
Russia 24
Saudi Arabia 24
Singapore 24
South Africa 24
Spain 24
Thailand 24
UAE 24
UK 24
US 24| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Nutritional Supplements | OTC & Nutraceuticals | $385 Bn | 6.8% |
| Over The Counter (OTC) Pharmaceuticals | OTC & Nutraceuticals | $178 Bn | 4.7% |
| Oncology/Cancer Drugs | Pharmaceuticals | $177 Bn | 8.4% |
| Gastrointestinal Drugs | Pharmaceuticals | $54 Bn | 4.6% |
| Biosimilars | Pharmaceuticals | $36.9 Bn | 24.9% |
| Over The Counter (OTC) Vitamins and Minerals | OTC & Nutraceuticals | $32 Bn | 5.5% |
| Contraceptives Drugs | Pharmaceuticals | $25.2 Bn | 6.8% |
| Over The Counter (OTC) Analgesics | OTC & Nutraceuticals | $22 Bn | 3.4% |
| Anti-Depressants Drugs | Pharmaceuticals | $18 Bn | 2.7% |
| Bone & Joint Health Supplements | OTC & Nutraceuticals | $12 Bn | 6.4% |
| Atopic Dermatitis Drugs | Pharmaceuticals | $11.2 Bn | 12.2% |
| Epilepsy Drugs | Pharmaceuticals | $9.6 Bn | 3.5% |
| Over The Counter (OTC) Sleep Aid Products | OTC & Nutraceuticals | $5.3 Bn | 4% |
| Over The Counter (OTC) Ophthalmic Drugs | OTC & Nutraceuticals | $3.6 Bn | 4.5% |
| Eye Health Supplements | OTC & Nutraceuticals | $3.1 Bn | 6.2% |
| Osteoporosis Supplements | OTC & Nutraceuticals | $3.1 Bn | 6.5% |
| Iron Supplement | OTC & Nutraceuticals | $2 Bn | 6.5% |
| Abuse Deterrent Opioids | Pharmaceuticals | – | – |
| Alopecia areata | Healthcare Services | – | – |
| Aminoglycosides | Pharmaceuticals | – | – |
| Anti-Nerve Growth Factor | Pharmaceuticals | – | – |
| Atherosclerosis Drugs | Pharmaceuticals | – | – |
| Axial Spondyloarthritis (axSpA) | Pharmaceuticals | – | – |
| Biosimilar Monoclonal Antibodies | Pharmaceuticals | – | – |
Named as key players in the same markets as Pfizer Inc. (number of shared markets).
Novartis AG12 shared markets
Merck & Co., Inc.9 shared markets
Johnson & Johnson8 shared markets
AstraZeneca7 shared markets
Sanofi7 shared markets
Bayer AG5 shared markets
Teva Pharmaceutical Industries Ltd.5 shared markets
Abbott Laboratories4 shared markets